Pioneering high-yield cell suspension line
Long before many AAV manufacturers existed, we recognized a universal need that crosses all AAV therapeutics – the need for a process that increases production and lowers cost. In 2010, we introduced Pro10™, a best-in-class cell line for generating novel AAV therapeutics. Our system uses a human embryonic kidney (HEK)-based cell line in serum-free suspension media to develop and produce AAV vectors at scales and yields that are the highest in the industry.
Pro10™ was the first HEK293 based suspension cell line to achieve high-yield AAV manufacturing without using any human or animal derived by-products to grow in bioreactors. This results in faster, safer, and highly scalable AAV vector manufacturing that sets new standards for the industry.
Pro10™ is used in AskBio’s Viralgen manufacturing facilities and is licensed by leading global biopharma companies.
“We strive to translate therapeutics into the clinic faster, safer and with greater predictability by advancing technology that increases scale and lowers cost of production.”
Josh Grieger, PhD
Chief Technology Officer